AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA
→ AstraZeneca swept out two early-stage cancer drugs in its Q4 call on Friday. Out to the dustbin goes the anti-ASCT2 antibody-drug conjugate MEDI7247 and a combination of oleclumab and AZD4635 — combining 2 inhibitors for CD73 and A2A — for EGFRm non-small cell lung cancer. Novartis has also been at work on a similar combination.
→ After the FDA waved its $186,000 rare cancer drug Tazverik (tazemetostat) to the market for ES, a type of soft tissue sarcoma, last month, Epizyme announced that the FDA has accepted their sNDA for patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. The regulatory body granted priority review and a PDUFA date of June 18, 2020.
→ Amid a coronavirus outbreak and as drugmakers scramble to develop new treatments for a disease now dubbed COVID-19, the US Department of Health and Human Services has launched the Foundry for American Biotechnology for future health security threats. The initiative will be housed in Manchester, New Hampshire and co-managed by the Advanced Regenerative Manufacturing Institute. The goal is to develop projects that industry partners will then commercialize.
“The Foundry’s first project will focus on maturing and validating small, portable, automated devices that could be transported easily to disaster locations to make necessary medicines on-site,” the announcement from earlier this week read.